# AbbVie

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/abbvie
Canonical HTML page: https://getyourbrief.com/entity/abbvie

## Timeline

- **2029-01-01**: Operations Online — New facilities expected to begin full-scale production of neuroscience and metabolic drugs.
- **2029-01-01**: Operational Launch — The new facilities are expected to come online and begin API production.
- **2029-01-01**: Operational Launch — The North Chicago facilities are expected to begin full-scale API production.
- **2029-01-01**: Operational Launch — New facilities expected to come online to support next-gen drug production.
- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-07-23**: Clarification on US Primary Endpoint — Companies publicly disclosed the trial missed the US primary endpoint of overall survival.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-06-12**: EHA 2026 Presentation — Additional study results presented at the European Hematology Association Congress.
- **2026-03-21**: Construction Start — Anticipated groundbreaking for the two new manufacturing plants.
- **2026-03-20**: Construction Start — Groundbreaking expected for the two new advanced manufacturing facilities.
- **2026-03-20**: Construction Start — Groundbreaking expected for the two new advanced manufacturing sites.
- **2026-03-20**: Construction Start — Anticipated ground-breaking for the two new advanced manufacturing sites.
- **2026-03-04**: Earnings Release — Company reports Q4 beat and issues bullish 2026 revenue guidance.
- **2026-03-03**: TD Cowen Conference — AbbVie management is scheduled to speak at the TD Cowen Health Care Conference.
- **2026-02-26**: DOJ Legal Support — The Department of Justice backs AbbVie in its challenge against a Colorado drug discount program law.

## Recent coverage (18 stories, network-wide)

### Epcoritamab Trial Misses Survival Goal—What It Means for DLBCL Patients
2026-08-01 11:31:34 · Sector: health · Sentiment: Neutral · Impact: 6/10 · Sources: 2

For healthcare providers treating relapsed/refractory DLBCL, the failure of epcoritamab to improve overall survival in a Phase 3 confirmatory trial raises critical questions about its long-term benefit over chemoimmunotherapy, even though the drug is already available under accelerated approval.
Full story: https://gethealthbrief.com/story/epcoritamab-survival-miss-dlbcl-patient-care

### Epcoritamab Phase 3 OS Miss Clouds $300M Revenue Stream for AbbVie and Genmab
2026-08-01 11:31:26 · Sector: bio · Sentiment: Neutral · Impact: 6/10 · Sources: 2

The Phase 3 EPCORE DLBCL-1 trial of epcoritamab failed its US overall survival endpoint, jeopardizing full approval and the drug's growing $300 million annual sales. This clarification deepens the competitive threat from other bispecifics with survival data.
Full story: https://getbiobrief.com/story/epcoritamab-phase3-os-miss-revenue-risk

### How Rinvoq and Skyrizi Will Drive 21.5% EPS Growth at Q2 Print
2026-07-28 01:06:23 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

AbbVie's second-quarter results, expected to show $3.61 EPS, hinge on the continued clinical and commercial success of Rinvoq and Skyrizi. The Apogee deal underscores a deepening immunology pipeline as Humira fades into the rearview.
Full story: https://getbiobrief.com/story/abbvie-q2-2026-rinvoq-skyrizi-growth

### IHE vs IXJ: 0.39% vs 0.41% Fees — Which Healthcare ETF Wins?
2026-07-19 06:02:54 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

The iShares U.S. Pharmaceuticals ETF (IHE) and iShares Global Healthcare ETF (IXJ) differ in expense ratios (0.39% vs 0.41%), AUM ($1.4B vs $4.1B), and diversification (56 vs 110 holdings). For finance professionals, the 0.02% fee gap may tip the scales for cost-conscious portfolios, but liquidity and global exposure often justify IXJ's slightly higher expense.
Full story: https://getfinancebrief.com/story/ihe-ixj-healthcare-etf-fee-comparison

### Phase 3: Epcoritamab Combo Cuts DLBCL Progression Risk by 60%
2026-07-11 23:08:35 · Sector: health · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

A fixed-duration bispecific antibody plus lenalidomide dramatically improved progression-free survival over standard salvage chemoimmunotherapy in relapsed/refractory DLBCL, potentially offering healthcare systems a more effective and less toxic outpatient option while reshaping treatment guidelines and resource utilization.
Full story: https://gethealthbrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-60-percent-risk-reduction-health

### Epcoritamab-Lenalidomide Hits Phase 3 PFS Goals: 60% Risk Reduction
2026-07-11 23:08:27 · Sector: bio · Sentiment: Strongly positive · Impact: 8/10 · Sources: 3

AbbVie and Genmab's bispecific antibody epcoritamab combined with lenalidomide delivered a hazard ratio of 0.40 in a pivotal DLBCL trial, setting the stage for regulatory filings and a potential second-line market expansion that could challenge CAR-T dominance and redefine the bispecific landscape.
Full story: https://getbiobrief.com/story/epcoritamab-lenalidomide-phase3-dlbcl-biotech-abbv-gmab

### UCB Commits $2B to Atlanta Manufacturing Hub to Fuel U.S. Growth
2026-03-24 23:54:36 · Sector: bio · Sentiment: Positive · Impact: 6/10 · Sources: 2

Belgian biopharma leader UCB has announced a massive $2 billion investment to construct a new manufacturing facility in suburban Atlanta, Georgia. The project is expected to create 330 high-tech jobs and significantly enhance the company's production capacity for its growing immunology and neurology portfolios.
Full story: https://getbiobrief.com/story/ucb-atlanta-manufacturing-expansion-2-billion

### UCB Commits $2B to Atlanta Manufacturing Hub Amid Biologic Growth
2026-03-24 23:54:02 · Sector: health · Sentiment: Positive · Impact: 6/10 · Sources: 2

Belgian biopharma giant UCB has announced a massive $2 billion investment to establish a new manufacturing plant in suburban Atlanta, creating 330 high-skilled jobs. The move strengthens UCB's U.S. footprint as it scales production for its high-growth immunology portfolio.
Full story: https://gethealthbrief.com/story/ucb-atlanta-2b-manufacturing-investment

### Top Dividend Picks: Analyzing Yield and Stability in a Volatile Market
2026-03-21 21:53:19 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A new screening of high-conviction dividend stocks highlights leaders across healthcare, energy, and technology sectors. As investors seek defensive positioning, these seven companies represent a blend of dividend growth and capital preservation potential.
Full story: https://getfinancebrief.com/story/dividend-stocks-to-watch-march-2026

### Evolus Surges on Q4 Beat as Jeuveau Gains Ground in Medical Aesthetics
2026-03-05 22:42:10 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 4

Evolus reported record Q4 2025 financial results, triggering a significant stock rally following a revenue beat and robust 2026 guidance. The company's performance underscores the resilience of the medical aesthetics market and the growing adoption of its flagship neurotoxin, Jeuveau.
Full story: https://gethealthbrief.com/story/evolus-q4-2025-earnings-analysis-jeuveau-growth

### RBC Capital Bullish on AbbVie: Initiates Coverage with Outperform Rating
2026-02-27 14:47:04 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has initiated coverage of AbbVie with an 'Outperform' rating, signaling confidence in the company's ability to navigate the post-Humira landscape. Analysts believe the market has over-discounted the growth potential of AbbVie's next-generation immunology drugs and its durable aesthetics portfolio.
Full story: https://getfinancebrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

### RBC Capital Initiates AbbVie Coverage with Outperform Rating
2026-02-27 14:46:31 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

RBC Capital has launched coverage of pharmaceutical giant AbbVie with an Outperform rating, signaling confidence in the company's growth trajectory. The initiation suggests that market concerns regarding biosimilar competition for Humira are overstated as newer immunology assets gain significant market share.
Full story: https://getbiobrief.com/story/rbc-capital-abbvie-outperform-rating-analysis

### Savara vs. Enanta: Divergent Paths in Rare Respiratory and Virology Markets
2026-02-27 03:44:21 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A comparative analysis of Savara and Enanta Pharmaceuticals reveals a stark contrast between a de-risked rare disease specialist and a virology firm navigating a pipeline transition. While Savara gains momentum from Phase 3 success in aPAP, Enanta continues to leverage its royalty-based financial foundation to fund high-stakes antiviral trials.
Full story: https://getbiobrief.com/story/savara-enanta-biotech-comparison-2026

### AbbVie Commits $380M to U.S. Manufacturing in $100B Reshoring Push
2026-02-25 00:14:40 · Sector: bio · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand its manufacturing capabilities in North Chicago, Illinois, marking the first major step in a decade-long $100 billion commitment to U.S. research and development. The move aligns with federal efforts to localize pharmaceutical supply chains and reduce drug prices through direct-to-patient initiatives like TrumpRx.
Full story: https://getbiobrief.com/story/abbvie-380-million-us-manufacturing-investment

### AbbVie Commits $380M to U.S. Manufacturing Amid $100B Domestic Pivot
2026-02-25 00:14:05 · Sector: health · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long commitment to U.S. R&D. The initiative aims to localize active pharmaceutical ingredient production while integrating with the Trump administration's 'TrumpRx' program to lower drug costs.
Full story: https://gethealthbrief.com/story/abbvie-380m-us-manufacturing-investment

### AbbVie Commits $380M to U.S. API Production in $100B Supply Chain Pivot
2026-02-25 00:13:32 · Sector: supply · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has announced a $380 million investment to expand active pharmaceutical ingredient (API) manufacturing in North Chicago, marking the first major step in a $100 billion decade-long commitment to U.S. R&D and production. The move aligns with federal efforts to reshore critical drug supply chains and lower costs through direct-to-patient channels like TrumpRx.
Full story: https://getsupplybrief.com/story/abbvie-380m-us-manufacturing-investment

### AbbVie’s $380M U.S. Expansion: A Blueprint for High-Skilled Job Growth
2026-02-25 00:09:21 · Sector: hr · Sentiment: Positive · Impact: 7/10 · Sources: 3

AbbVie has committed $380 million to expand its North Chicago manufacturing campus, marking the first major step in a $100 billion decade-long investment pledge. The project aims to localize the production of active pharmaceutical ingredients and is expected to create hundreds of specialized engineering and technical roles by 2029.
Full story: https://gethrbrief.com/story/abbvie-380m-us-manufacturing-expansion-talent-impact

### Genmab Faces Profit Squeeze as R&D for ADC Pipeline Weighs on 2026 Outlook
2026-02-19 08:27:49 · Sector: finance · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Genmab A/S reported full-year 2025 revenue of $3.72 billion, missing analyst estimates despite strong growth in its core oncology portfolio. The company is prioritizing long-term growth through its $1.8 billion ProfoundBio acquisition and the global rollout of Epkinly, leading to a temporary contraction in net profit margins.
Full story: https://getfinancebrief.com/story/genmab-q4-2025-earnings-analysis-rd-spending

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.